Simulations Plus, Inc.

Simulations Plus develops software and provides consulting services for drug discovery and development, focusing on computational modeling and simulation of molecular properties and drug behavior in biological systems. The company's software platform uses artificial intelligence and machine learning to predict absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties of drug candidates. Core products include GastroPlus, which simulates human and animal pharmacokinetics and pharmacodynamics; DDDPlus and MembranePlus for biopharmaceutic modeling; and ADMET Predictor for chemistry-based property predictions. The company also offers mechanistic and mathematical modeling products for disease-specific applications, including DILIsym, NAFLDsym, and RENAsym, as well as the MonolixSuite for population pharmacokinetic and pharmacodynamic analysis.

The business operates through two segments: Software and Services. The software segment generates recurring revenue from licensing and subscription-based access to modeling platforms. The Services segment comprises clinical pharmacology consulting, which includes population modeling, exposure-response analyses, clinical trial simulations, and regulatory support, along with early drug discovery and quantitative systems pharmacology consulting.

The company serves pharmaceutical and biotechnology firms, agrochemical manufacturers, cosmetics and food companies, academic institutions, and regulatory agencies globally. Simulations Plus operates from its headquarters in Research Triangle Park, North Carolina, with approximately 212 full-time employees.